ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Vaginal estrogen preparations available in the United States for treatment of genitourinary syndrome of menopause (vulvovaginal atrophy)

Vaginal estrogen preparations available in the United States for treatment of genitourinary syndrome of menopause (vulvovaginal atrophy)
Preparation
(United States trade name)		 Available strengths Recommended regimen
Vaginal ring
Estring 7.5 mcg estradiol daily, released over 90 days Ring is inserted into the vagina by the patient or clinician. Ring is removed and replaced with a new ring every 90 days.
Vaginal insert
Imvexxy 4 mcg estradiol per vaginal insert Insert 1 tablet intravaginally daily for 2 weeks, followed by twice weekly. Dose may be increased to the 10 mcg insert according to clinical response.
Imvexxy,
Vagifem,
Yuvafem		 10 mcg estradiol per vaginal insert Insert 1 tablet intravaginally daily for 2 weeks, followed by twice weekly.
Vaginal cream
Premarin 0.625 mg conjugated estrogens per g of cream 0.5 g of cream intravaginally administered daily for 2 weeks, then reduce to twice weekly*; dose may be adjusted according to patient's symptoms and clinical response (range 0.5 to 2 g).
Estrace 100 mcg estradiol per g of cream 0.5 g of cream intravaginally administered daily for 2 weeks, then reduce to twice weekly*; dose may be adjusted according to patient's symptoms and clinical response (initial range: 0.5 to 4 g; maintenance range: 0.5 to 1 g).
For clinical indications and approach to dose adjustment, refer to UpToDate topic review of genitourinary syndrome of menopause (vulvovaginal atrophy) treatment.
* Our practice differs from the manufacturer's product information; refer to UpToDate topic for further information.
Prepared with data from: FDA prescribing information available at US National Library of Medicine NIH DailyMed website https://dailymed.nlm.nih.gov/dailymed/index.cfm (accessed on March 18, 2021) and The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society, Menopause: September 2020 - Volume 27 - Issue 9 - p 976-992.
Graphic 58506 Version 22.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟